Actos
Research shows that use of the diabetes drug Actos for more than one year increases the risk of bladder cancer by 40 percent. The Food and Drug Administration (FDA) mandated an Actos label update to reflect the bladder cancer risk in June 2011. This followed a review of a study conducted on 200,000 diabetes patients. The study
Read More